Zoetis Belgium S.A
USPTO PatentsView assignee record - 6 granted patents across 7 technology areas, recorded in grant years 2015–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Zoetis ranks #44,263 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 7 technology areas.
- #44,263
- of 49,997 US assignees by volume
- 10th percentile
- by Innovation Score (22.5/100)
- 10.7
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R44263 · Foreign Corporation #44,263 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #44,263/49,997
- PHOTO-FINISH ]Koninklije Philips
- CPC-NARROW A61P · 7 areas
- INNOV-THIN 22.5/100
- CLAIMS-PAR 10.7 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: ]Koninklije Philips N.V. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Zoetis’s 22.5 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Zoetis
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Zoetis Belgium · this assignee 22
Zoetis Belgium · this assignee
22 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Zoetis's Innovation Score is 22.5/100 (10th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Zoetis?
Each dot is one of Zoetis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Zoetis’s own 10.7 claims/patent is at or below the 16.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Zoetis's grants concentrate
Zoetis Belgium S.A is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2015. By volume, Zoetis sits between Zimmer US, Inc. and ]Koninklije Philips N.V..
Who files at Zoetis's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Zimmer US
Zimmer US, Inc.
6 patents
- Ziva Dynamics
Ziva Dynamics Inc.
6 patents
- Zivo Bioscience
Zivo Bioscience, Inc.
6 patents
- Zoe
Zoe Limited
6 patents
- Zogenix
Zogenix, Inc.
6 patents
- Zoltek
Zoltek Corporation
6 patents
- Zuca
Zuca, Inc.
6 patents
- ]Koninklije Phili…
]Koninklije Philips N.V.
6 patents
- Zoetis Belgium ◀
Zoetis Belgium S.A
6 patents
What this shows Zoetis holds 6 patents at rank #44,236, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Zoetis
By rank, the assignees closest to #44,236 in granted patent volume.
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Zoetis's primary technology class.
- The Regents of the University of California 1,387 in class
- Novartis AG 1,071 in class
- Merck Sharp & Dohme LLC 889 in class
- Bristol-Myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board of Regents of the University of Texas System 744 in class
- Hoffmann-La Roche Inc. 722 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 721 in class
Zoetis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
22 10th percentile higher than 10% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 16.7% |
| 2016 | 2 | 33.3% |
| 2018 | 2 | 33.3% |
| 2019 | 1 | 16.7% |
Which technologies does Zoetis Belgium S.A patent most?
Top 7 of 7 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Zoetis Belgium S.A's patent record in context - here's where to go next.
- Zoetis Belgium S.A's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
- Ranked #44,263 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Zoetis Belgium S.A against Zimmer US, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 22.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.